Plus the CBO runs the math on IRA-related costs for 2025 and come up with a real big number
And Blue Shield of California shows that health plans can acquire cheap biosimilar Humira without the help of a PBM
Plus new data on Part D premiums, Newsom torpedoes PBM reform, and a new study on the impact of real-time benefits info
Plus: What's up with Bernie and the PBMs?
Plus an object lesson in how bad data can turn into questionable journalism
The rest of yesterday's hearing: standard-issue, short-shelf-life manufactured drama. Barely worth the popcorn.
Plus what the FTC is asking for in its lawsuit against PBMs
And if you're really tuned into this particular fistfight, there's a 46Brooklyn analysis you need to digest
It's a big day for reports: there's a fantastic look at employer/health plan satisfaction with PBMs, too
And the 340B war of words escalates, but I'm not getting worked up until the legal briefs start flying
And Cigna/Evernorth/Express Scripts decides that the best way to make the FTC PBM report go away is to sue the snot out of the agency
Plus the implications of the sudden wave of subcutaneous meds for price controls, and CMS pushes back against the 'M3P' abbreviation that you like so much
